Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PYGL | P06737 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.40 |
| ▸ | FNTA | P49354 | 2/20 | 0.39 |
| ▸ | FNTB | P49356 | 2/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13583606 | 0.93 | MEN1 (0.44) | CA2MEN1KMT2APYGLCYP2C9 | |
| SCHEMBL2329271 | 0.91 | CA2 (0.46) | CA2PYGLCYP2C9KCNA5FNTA | |
| SCHEMBL13583111 | 0.91 | MEN1 (0.46) | CA2MEN1KMT2APYGLCYP2C9 | |
| SCHEMBL13583516 | 0.90 | MEN1 (0.43) | CA2MEN1KMT2APYGLCYP2C9 | |
| SCHEMBL13583525 | 0.90 | MEN1 (0.43) | CA2MEN1KMT2APYGLCYP2C9 | |
| SCHEMBL13822277 | 0.89 | MEN1 (0.40) | MEN1KMT2AKCNA5S1PR2S1PR1 | |
| SCHEMBL2328207 | 0.88 | CA2 (0.45) | CA2PYGLCYP2C9FNTAFNTB | |
| SCHEMBL2329801 | 0.87 | S1PR2 (0.46) | CA2PYGLCYP2C9FNTAFNTB | |
| SCHEMBL2326078 | 0.87 | S1PR2 (0.46) | CA2PYGLCYP2C9FNTAFNTB | |
| SCHEMBL2326953 | 0.87 | S1PR2 (0.46) | CA2PYGLCYP2C9FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2524686-B1 | PIGMENTATION-PREVENTING OR -AMELIORATING AGENT | POLA CHEM IND INC (JP) | 2017-06-21 | — | — | EP | disclosed |
| US-9066914-B2 | Prophylactic or ameliorating agent for pigmentation | POLA CHEMICAL INDUSTRIES INC. (JP) | 2015-06-30 | — | — | US | disclosed |
| EP-2524686-A1 | PIGMENTATION-PREVENTING OR -AMELIORATING AGENT | Pola Chemical Industries Inc. (JP) | 2012-11-21 | — | — | EP | disclosed |
| US-20120282203-A1 | PROPHYLACTIC OR AMELIORATING AGENT FOR PIGMENTATION | POLA CHEMICAL INDUSTRIES INC. (JP) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282203-A1 | PROPHYLACTIC OR AMELIORATING AGENT FOR PIGMENTATION | TYR, MC1R, NQO1 | CA2 894/4885MEN1 1487/4885KMT2A 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.